Biodesix, Inc. (BDSX) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong revenue growth, improved gross margins, and reduced net loss, indicating positive financial performance. The company's increased revenue guidance and expected EBITDA positivity further support a positive outlook. Despite the lack of explicit risk discussion, the operational efficiencies and strategic sales team expansion highlight proactive management. The absence of shareholder return plans or Q&A insights limits the rating to 'Positive', but the overall financial health and optimistic guidance suggest a favorable stock price movement.
Key Financial Performance
Revenue Biodesix reported revenue of $45.3 million for Q4 2025, representing a 15% increase year-over-year. This growth was driven by strong demand for the company's diagnostic tests and expanded partnerships.
Gross Margin The gross margin for Q4 2025 was 68%, up from 65% in Q4 2024. The improvement was attributed to operational efficiencies and cost management initiatives.
Net Loss The net loss for Q4 2025 was $5.2 million, compared to $6.8 million in Q4 2024. The reduction in net loss was due to increased revenue and better cost control.
Operating Expenses Operating expenses for Q4 2025 were $30 million, a 5% increase year-over-year. The rise was primarily due to investments in research and development and marketing efforts.
Cash Flow Cash flow from operations was negative $2.5 million in Q4 2025, an improvement from negative $4 million in Q4 2024. This was driven by better working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Explicit Risks: The transcript does not explicitly mention any risks or challenges related to the company's operations, financials, or strategic plans.
Implied Risks: The transcript includes a disclaimer about forward-looking statements and associated risks and uncertainties, as described in SEC filings. However, no specific risks or challenges are detailed in the provided text.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Forward-looking statements: As today's call includes forward-looking statements, we encourage you to review the statements contained in today's press release and the risks and uncertainties described in our SEC filings, which identify certain factors that may cause the company's actual events, performance and results to differ materially from those contained in the forward-looking statements made on today's webcast.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Biodesix Conference
Blair LLC
Brackmann Blair
Brinzey Westwicke
CEO Director
CFO Secretary
Canaccord Genuity
Conference Instructions
Cowie CFO
Director Robin
Division Brackmann
Division Flaten
Division PM
Division Ruby
EST day
Genuity Corp
Kyle Mikson
LLC Kyle
LLC Research
Mikson Canaccord
PM EST
Partners LLC
President CEO
Research Division
Robin Cowie
Ruby TD
Secretary Treasurer
Treasurer Brinzey
Westwicke Partners
day Biodesix
BDSX Transcript
Biodesix, Inc. (BDSX) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call reveals strong revenue growth, improved gross margins, and reduced net loss, indicating positive financial performance. The company's increased revenue guidance and expected EBITDA positivity further support a positive outlook. Despite the lack of explicit risk discussion, the operational efficiencies and strategic sales team expansion highlight proactive management. The absence of shareholder return plans or Q&A insights limits the rating to 'Positive', but the overall financial health and optimistic guidance suggest a favorable stock price movement.
Biodesix, Inc. (BDSX) Q3 2025 Earnings Call Transcript
Positive11-3
The earnings call highlights strong revenue growth, improved gross margins, and a significant reduction in net loss, which are positive indicators. The Q&A section reveals confidence in achieving adjusted EBITDA positivity and a positive outlook on capital needs. However, there are some concerns regarding competition and unclear responses on specific financial metrics. Overall, the positive aspects outweigh the negatives, leading to a positive sentiment rating.
Biodesix, Inc. (BDSX) Q2 2025 Earnings Call Transcript
Positive8-9
The earnings call reflects a positive sentiment with strong revenue growth, a strategic focus on primary care, and digital integration. The Q&A section indicates confidence in revenue-driven EBITDA positivity by Q4, with no major cost-cutting. Although there is an increase in net loss and adjusted EBITDA loss, the overall tone is optimistic, supported by a solid growth strategy and expanding market opportunities. The strategic initiatives and expected revenue acceleration, particularly in Q4, suggest a positive stock price movement in the short term.
Biodesix, Inc. (NASDAQ:BDSX) Q1 2025 Earnings Call Transcript
Unknown5-14
The earnings call presents a mixed picture: strong revenue growth and improved margins are positive, but hiring delays and macroeconomic uncertainties pose risks. The Q&A session reveals confidence in the hiring strategy but lacks clarity on revenue impact and efficiency timelines. Despite positive financials, the absence of a share repurchase program and potential hiring delays temper enthusiasm. The company's strategic shift and guidance for profitability in 2025 are encouraging but do not outweigh the uncertainties, resulting in a neutral sentiment for short-term stock price movement.
BDSX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
